APA (7th ed.) Citation

Müller, V., Hörner, M., Thill, M., Banys-Paluchowski, M., Schmatloch, S., Fasching, P. A., . . . Hartkopf, A. D. (2025). Real-world utilization of aromatase inhibitors, tamoxifen, and ovarian function suppression in premenopausal patients with early hormone receptor-positive, HER2-negative breast cancer with increased recurrence risk. The breast, 81, . https://doi.org/10.1016/j.breast.2025.104458

Chicago Style (17th ed.) Citation

Müller, Volkmar, et al. "Real-world Utilization of Aromatase Inhibitors, Tamoxifen, and Ovarian Function Suppression in Premenopausal Patients with Early Hormone Receptor-positive, HER2-negative Breast Cancer with Increased Recurrence Risk." The Breast 81 (2025). https://doi.org/10.1016/j.breast.2025.104458.

MLA (9th ed.) Citation

Müller, Volkmar, et al. "Real-world Utilization of Aromatase Inhibitors, Tamoxifen, and Ovarian Function Suppression in Premenopausal Patients with Early Hormone Receptor-positive, HER2-negative Breast Cancer with Increased Recurrence Risk." The Breast, vol. 81, 2025, https://doi.org/10.1016/j.breast.2025.104458.